unknown
Stage
1
Investors
About
Advemto develops technology to map complex cell functions to genetic sequences at a large scale, aiming to eliminate bottlenecks in preclinical validation for next-generation therapeutics and TechBio without requiring new instruments.
Explore Advemto's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.